Is Bal Pharma overvalued or undervalued?

As of 14 February 2025, Bal Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently assessed as fairly valued. Key ratios include a PE ratio of 22.15, an EV to EBITDA of 9.81, and a ROE of 11.14%.
In comparison to its peers, Bal Pharma's PE ratio is lower than Sun Pharma's 35.25 and Divi's Lab's 79.33, which are categorized as expensive and very expensive, respectively. Additionally, it is on par with Cipla's attractive rating at a PE of 22.99. While Bal Pharma has experienced a decline in stock price year-to-date, it has outperformed the Sensex in the short term, with a 1-week return of 3.08% compared to the Sensex's 1.42%.